Abstract

The genetic bases for the congenital disorders of glycosylation (CDG) continue to expand, but how glycosylation defects cause patient phenotypes remains largely unknown. Here, we combined developmental phenotyping and biochemical studies in a potentially new zebrafish model (pmm2sa10150) of PMM2-CDG to uncover a protease-mediated pathogenic mechanism relevant to craniofacial and motility phenotypes in mutant embryos. Mutant embryos had reduced phosphomannomutase activity and modest decreases in N-glycan occupancy as detected by matrix-assisted laser desorption ionization mass spectrometry imaging. Cellular analyses of cartilage defects in pmm2sa10150 embryos revealed a block in chondrogenesis that was associated with defective proteolytic processing, but seemingly normal N-glycosylation, of the cell adhesion molecule N-cadherin. The activities of the proconvertases and matrix metalloproteinases responsible for N-cadherin maturation were significantly altered in pmm2sa10150 mutant embryos. Importantly, pharmacologic and genetic manipulation of proconvertase activity restored matrix metalloproteinase activity, N-cadherin processing, and cartilage pathology in pmm2sa10150 embryos. Collectively, these studies demonstrate in CDG that targeted alterations in protease activity create a pathogenic cascade that affects the maturation of cell adhesion proteins critical for tissue development.

Highlights

  • Congenital Disorders of Glycosylation (CDG) are a heterogeneous group of genetic diseases caused by defects in enzymes, transporters, and trafficking factors needed for protein and lipid glycosylation [1]

  • M1P is a precursor for guanosine diphosphate (GDP)-mannose, a nucleotide sugar essential for the synthesis of lipid linked oligonucleotide precursors needed for N-linked glycosylation [4]

  • The evidence for disease and tissue-specific changes in glycosylation in these conditions is abundant, and in several cases alterations in glycan structure has been linked to the impaired function of specific glycoproteins [40,41,42,43]

Read more

Summary

Introduction

Congenital Disorders of Glycosylation (CDG) are a heterogeneous group of genetic diseases caused by defects in enzymes, transporters, and trafficking factors needed for protein and lipid glycosylation [1]. M1P is a precursor for guanosine diphosphate (GDP)-mannose, a nucleotide sugar essential for the synthesis of lipid linked oligonucleotide precursors needed for N-linked glycosylation [4]. Defects in PMM2 limit the production of GDP-mannose, causing reduced glycosylation of serum glycoproteins and numerous clinical manifestations. To date no underglycosylated glycoprotein has been mechanistically linked to disease in an affected tissue. This barrier has created a major gap in our understanding of the molecular and cellular mechanisms driving

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call